
June 30 (Reuters) - INmune Bio Inc INMB.O:
INMUNE BIO REPORTS KEY FINDINGS FROM PHASE 2 MINDFUL TRIAL OF XPRO™ IN EARLY ALZHEIMER’S DISEASE
INMUNE BIO INC - PHASE 2 MINDFUL TRIAL DID NOT MEET PRIMARY COGNITIVE ENDPOINT IN MITT POPULATION
INMUNE BIO INC - XPRO TREATMENT WELL-TOLERATED AND SAFE IN HIGH RISK APOE4+/+ PATIENTS
INMUNE BIO INC - TO SCHEDULE END-OF-PHASE 2 MEETING WITH FDA IN Q4 2025